The GLP-1 market is experiencing a robust surge in demand globally, driven by the increasing burden of type 2 diabetes and obesity, rising public awareness of metabolic health, and growing adoption of novel non-insulin therapies. Glucagon-like peptide-1 (GLP-1) analogs and receptor modulators have become a cornerstone in modern diabetes management and weight reduction programs, especially as...